AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05886959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session 7: Weaving Wisdom and Compassion into Daily Life
Description: Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants.
Study NCT05886959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session 8: Living with the Heart
Description: The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application.
Study NCT05387785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG-3070
Description: Orally administered tyrosine kinase inhibitor capsule.
Study NCT05387785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered placebo capsule
Study NCT04938726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Monoester
Description: Ketone supplement will be taken by mouth at a dose of 15 mL twice per day
Study NCT04938726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ketone Monoester
Description: Ketone supplement will be taken by mouth at a dose of 15 mL twice per day
Study NCT06652880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital technology
Description: The digital app is a customized comprehensive self-management platform designed to provide recovery and parenting support for individuals with substance use disorders.
Study NCT06652880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bibliotherapy
Description: Bibliotherapy control group will receive parenting book what to expect the first year.
Study NCT04732637 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Test At Home's Proprietary Lollipop Buccal Cavity Swab
Description: Self-collected Test At Home's proprietary Lollipop Buccal Cavity Swab with VTM.
Study NCT05151887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle protein synthesis
Description: The meals contain a total of 0.45 g protein/kg body mass (36 g protein for an 80 kg person). To account for differences in body mass, the investigators will scale the meal content to ensure 0.45 g/kg body mass for different body mass ranges (i.e., 65-75 kg, 75-85 kg, etc.). As such, carbohydrate, fat, and total energy content of the meals will also be scaled to body mass. The test meals are composed out of regular whole food items which will be purchased from local shops. The muscle protein synthetic response following meal ingestion will be assessed by the use of stable isotope tracer methodology
Study NCT06231992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: opioid anaesthesia
Description: I.V Fentanyl (1-2ug/kg) before induction of general anesthesia with I.V propofol (1-2mg/kg), atracurium (0.5mg/kg). Intermittent boluses of fentanyl will be given intraoperatively when needed to maintain the change in hemodynamics within 20 % of the baseline.
Study NCT06231992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Opioid free anaesthesia
Description: * IV Ketamine (0.25-0.5 mg/kg) before induction of general anesthesia with I.V propofol (1-2 mg/kg), atracurium (0.5mg/kg) followed by(0.25mg /min) infusion of ketamine for maintenance~* Dexamethasone I.V (8 mg) will be given before induction of general anesthesia.~* magnesium sulphate (20 mg/kg)in 100ml saline within 10 mints Followed by infusion of magnesium sulphate at rate of (10mg/kg/h).
Study NCT04922606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: US ot the GSV
Description: Ultrasound of the Great Saphenous Vein
Study NCT04701190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenalin 10 microgram bolus
Description: The noradrenaline bolus dosage of 10 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
Study NCT04701190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenaline 5 microgram bolus
Description: The noradrenaline bolus dosage of 5 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
Study NCT04701190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenaline 0.1 microgram/kg/minute infusion
Description: Infusion dosage: 0.1 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus.
Study NCT04701190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenaline 0.05 microgram/kg/minute infusion
Description: Infusion dosage: 0.05 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus.
Study NCT04701190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion dosage: 0.075 microgram/kg/minute infusion
Description: nfusion dosage: 0.075 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus.
Study NCT04701190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Spinal anesthesia using 0.5% 10 milligram heavy bupivacaine plus 12.5 microgram fentanyl
Study NCT06415643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Islet organoids transplantation
Description: autologous transplantation of ex vivo expanded islet organoids.
Study NCT05262205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: measuring depth of anesthesia and its relation to the globe
Description: measuring feasibility of BIS monitor in detecting depth of anesthesia in pediatric population and whether it will be beneficial as a tool for helping anesthesiologist in maintaining central globe alignment
Study NCT05564663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD Coach App + Brief Support
Description: PTSD Coach App + Brief Support will include downloading the PTSD Coach App for personal use and four, brief (\<20 minutes), weekly, individual support sessions. The sessions will focus on the instruction and encouragement of App use and activities (i.e., assessments, self-management strategies, and psychoeducational readings).
Study NCT05564663 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: EUC will consist of one brief session (with brochure) of PTSD and AUD psychoeducation and referral information for mental health clinics that provide PTSD services, with encouragement to schedule an appointment at one of the listed clinics to discuss PTSD-related symptoms.
Study NCT05254795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Molecular tumor board assisted care
Description: Participants in this group will obtain recommendations for care from the molecular tumor board.
Study NCT05232604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 30-45 minutes of aerobic exercise in a cycle ergometer will be applied in three different intensities (low, moderate and high) along 12 weeks of treatment.
Study NCT05232604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck motor control exercise
Description: An specific neck motor control exercise targeted to the neck flexor and extensor muscles supervised by a physical therapist will be applied during 12 weeks of treatment.
Study NCT05444374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Recombinant anti-PD-1 humanized monoclonal antibody injection
Study NCT05444374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Humanized anti-VEGF monoclonal antibody injection
Study NCT05756101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Research on the application of novel restraint devices in postoperative patient safety management in cardiac surgery
Description: According to the individual characteristics of ICU patients and the needs of patients, a new type of restraint device was innovatively made and the effectiveness and safety of the new restraint device were studied, which provided clinical reference and theoretical basis for standardizing postoperative patient restraint.
Study NCT04195334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: internal fixation by IMN
Description: using retrograde or antegrade IMN for femooral fractures fixation using a fit nail to the femoral intramedullary canaland follow up for union
Study NCT05574673 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: Patients receive standard of care treatment according to local and national guidelines
Study NCT06127862 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education group
Description: Students in the experimental group were educated about environmental health and microplastica, and nursing interventions were made. The training was organized for twenty minutes in each session, with a total of four sessions at two-week intervals.
Study NCT06127862 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No training was given
Description: No training was given
Study NCT06326346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liporaxel
Description: Liporaxel 200mg/m2 twice daily orally on day 1, 8, and 15 every 4 weeks (1 cycle = 4 weeks)
Study NCT05443256 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Figure 8 coil stimulation
Study NCT05443256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Figure 8 coil stimulation
Study NCT04395196 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Choline bitartrate
Description: Provided in beverage form
Study NCT04395196 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provided in beverage form
Study NCT05784883 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: A comprehensive 2- and 3-dimensional transthoracic echocardiography (TTE) assessment of the tricuspid valve and right side of the heart at baseline.
Study NCT06243640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buagafuran capsules, 15mg/ capsule
Description: Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;
Study NCT06243640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buagafuran capsules mimic, 0mg/ capsule
Description: Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;
Study NCT06243640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buagafuran capsules mimic, 0mg/ capsule
Description: Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;
Study NCT05210387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Duration of therapy
Description: In experimental group patients with severe infection caused by MDR-GNB and who present a clinical response on day 7 (±1) of adequate antimicrobial therapy, the therapy will be suspended.~The active control group will continue therapy until day 14 (±1).
Study NCT05210387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of therapy
Description: In experimental group patients with severe infection caused by MDR-GNB and who present a clinical response on day 7 (±1) of adequate antimicrobial therapy, the therapy will be suspended.~The active control group will continue therapy until day 14 (±1).
Study NCT06452095 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric Oxygen therapy
Description: The SECHRIST INDUSTRIES Models 3600 and 4100 (H/HR) Hyperbaric Chambers are Monoplace Pressure Chambers designed to administer oxygen at near 100% concentration as the hyperbaric treatment gas, up to 3.0 atmospheres absolute (ATA) of pressure (29.4 psig). This study will utilize the 3600 and 4100 (H/HR) Hyperbaric Chambers located at Toronto General Hospital, Rouge Valley Hyperbaric Medicine Unit and Restore Hyperbaric Oxygen \& Medical Centre.
Study NCT06452095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen therapy
Description: The SECHRIST INDUSTRIES Models 3600 and 4100 (H/HR) Hyperbaric Chambers are Monoplace Pressure Chambers designed to administer oxygen at near 100% concentration as the hyperbaric treatment gas, up to 3.0 atmospheres absolute (ATA) of pressure (29.4 psig). This study will utilize the 3600 and 4100 (H/HR) Hyperbaric Chambers located at Toronto General Hospital, Rouge Valley Hyperbaric Medicine Unit and Restore Hyperbaric Oxygen \& Medical Centre.
Study NCT03827031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mutlidisciplinary medication Review (MMR)
Description: The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted
Study NCT03827031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up
Description: Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.~Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.~Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted.
Study NCT05250739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training was performed with resistance bands. The band was fastened to the unaffected ankle, while the participant was told to perform front and back pulls, as well as adduction and abduction movements with the affected ankle. They were told to control the ankle movement and to make it slow. Since the first day, they were told to perform the exercise pulling the band as if they wanted to make the resistance of 5 on a scale from 0 to 10.
Study NCT05250739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: consisted in a multi-station training with 6 exercises, increasing the difficulty progressively as the participants controlled the execution. The exercises were all performed barefoot and with the injured foot. These were a combination of standing and jumping exercises involving the injured ankle. The participants did not start the next progression until they perform a complete circuit in the level before.
Study NCT04366115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVM0703
Description: Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.
Study NCT04366115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion in normal saline over 1 hour to patients.
Study NCT04936737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine supplementation
Description: The supplementation will be administrated in the dosage of 20mg.kg-1. On the first and the sixth (last one), one dose of beta-alanine will be taken. On the other four days of supplementation, the volunteers will take 2 doses (20mg.kg-1) of Beta-alanine.
Study NCT04936737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise
Description: The HIIE sessions will consist of 10 series of 1 min of effort, divided into two blocks of 5 series each. There will be an interval of 5 min of passive recovery; within each block, the interval between sets will be 1 min of active recovery. The exercise will be conducted in a mechanical brake cycle ergometer, with load applied by placing washers on a load plate (Biotec 2100, Cefise, Brazil).
Study NCT05152498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fu Zheng Jie Du Hua Yu therapy
Description: Fu Zheng Jie Du Hua Yu is a Chinese herbal compound
Study NCT06337695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: 300 mg IV at weeks 0, 3, 6, 14, and 22
Study NCT06337695 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg IV at weeks 0, 3, 6, 14, and 22
Study NCT04627363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
Study NCT04627363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg intravenously every 3 weeks
Study NCT04627363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks
Study NCT05706571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group (skill laboratory), experimental group 1 (Banner model) and experimental group2 (augmented reality mobile application)
Description: In the research, the control group will form the control group of both experiment one and experiment two. In the creation of quantitative and qualitative data, it will be formed in three groups, two of which are the experimental group and one is the control group. While forming the experimental and control groups of the research, it is planned to ensure homogeneity between the groups by making random and unbiased selection. It is planned to do a pre-test before applying the child patient end-of-life care module of nursing students of teaching with augmented reality and Benner model to the experimental and control groups.
Study NCT05863871 — intervention group
Intervention type: DRUG
Intervention: Linperlisib
Description: 80 mg, qd
Study NCT05072795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Task (TSST)
Description: The TSST is a standardized psychological stress challenge which provokes a stress response in a laboratory setting. During the task, saliva samples will be collected for hormone testing along with physiological and subjective measures.
Study NCT04722627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-752
Description: Parallel Assignment
Study NCT04722627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parallel Assignment
Study NCT03958929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: The film follows the journey of an elderly patient scheduled to undergo glaucoma surgery, beginning with a face-to-face Q\&A health session with an eye doctor. After surgery, the patient talks about his post-operative eyesight and discusses the benefits of early diagnosis and glaucoma surgery for treatment with his community.
Study NCT05876806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis
Study NCT05876806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.
Study NCT05027867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: Administered by mouth
Study NCT05349357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sliding Neural mobilization
Description: Sliding neural mobilization to femoral, sciatic and tibial nerve
Study NCT05349357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tensioner Neural mobilization
Description: Tensioner neural mobilization to femoral, sciatic and tibial nerve
Study NCT05349357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: Stretching exercises
Study NCT05349357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS
Study NCT05733442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU entails medication to support patients' recovery (i.e., the partial opioid agonist, buprenorophine + naloxone/ Suboxone gel films), in-person case management and behavioral health intervention (i.e., in-person group and individual counseling), and referrals to other health care and behavioral health services.